138888-98-9

Basic information

• Product Name: (E)-N'-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide
• Synonyms: (E)-N'-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide;N'-(5-broMo-2-pyridinyl)-N,N-diMethyl-;5- bromo -2- pyrimidine -N, N-dimethyl formamidine;N'-(5-bromopyridin-2-yl)-N,N-dimethylformamidine
• CAS NO: 138888-98-9
• Molecular Formula: C₈H₁₀BrN₃
• Molecular Weight: 228.092
• Mol File: 138888-98-9.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (E)-N'-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N'-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide(138888-98-9)
• EPA Substance Registry System: (E)-N'-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide(138888-98-9)

Safety Data

• Hazardous Substances Data: 138888-98-9(Hazardous Substances Data)

Usage

General Description

(E)-N'-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide is a chemical compound with the molecular formula C9H10BrN3 and a molecular weight of 244.10 g/mol. It is a formamidine derivative with a bromopyridine group attached to the N' position and two dimethylamino groups attached to the formimidamide moiety. (E)-N'-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide is commonly used in the synthesis of various pharmaceuticals and agrochemicals due to its versatile reactivity and ability to participate in a range of organic reactions. Additionally, it has shown potential as a building block in drug discovery and development efforts. However, its specific biological or pharmacological properties are not well-documented, and further research is needed to fully understand its potential applications.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 68-12-2 N,N-dimethyl-formamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 1989745-33-6 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-3-carbonitrile 
• 474708-98-0 6-bromoimidazo[1,2-a]pyridine-3-carbonitrile 
• 356560-80-0 6-bromo[1,2,4]triazolo[1,5-a]pyridine 
• 30384-96-4 6-bromoimidazo[1,2-a]pyridine-3-carbaldehyde 
• 328062-45-9 6-phenylimidazo[1,2-a]pyridine 
• 870773-63-0 trans-tert-butyl [(1S,2S)-1-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-3-(dimethylamino)-3-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-cyclohexyl)propyl]carbamate 
• 870773-62-9 cis-tert-butyl [(1S,2S)-1-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-3-(dimethylamino)-3-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-cyclohexyl)propyl]carbamate 
• 690258-08-3 1-[(2S,3S and 3R)-2-(tert-butoxycarbonylamino)-3-carboxy-3-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)1-oxopropanyl]-3,3-difluoropyrrolidine 

Relevant articles and documents

Imidazo[1,2-a]pyridines linked with thiazoles/thiophene motif through keto spacer as potential cytotoxic agents and NF-κB inhibitors

A series of new imidazo[1,2-a]pyridine linked with thiazole/thiophene motif through a keto spacer were synthesized and tested for their cytotoxic potential against three human cancer cell lines including A549, HeLa and U87-MG using MTT assay. Compounds A2

Preparation method of 6-bromoimidazo[1.2-a]pyridine-3-formaldehyde

The invention relates to a preparation method of 6-bromoimidazo[1.2-a]pyridine-3-formaldehyde. The method comprises the following steps: 1, adding 2-amino-5-bromopyridine and N,N-dimethylformamide dimethyl acetal into a reactor to react, and stirring to react to obtain an N,N-dimethyl-N'-2-(5-bromo-pyridine)yl-formamidine intermediate; 2, adding the N,N-dimethyl-N'-2-(5-bromo-pyridine)yl-formamidine intermediate obtained in the step 1 into a solvent, adding chloroacetaldehyde, and carrying out a reaction to obtain a solid mixture; 3, dissolving the solid mixture in ethyl acetate, washing withwater and saturated edible salt water, drying with anhydrous sodium sulfate, filtering, and removing ethyl acetate to obtain a 6-bromoimidazo[1.2-a]pyridine-3-formaldehyde crude product; and 4, recrystallizing the 6-bromoimidazo[1.2-a]pyridine-3-formaldehyde crude product, and filtering to obtain a 6-bromoimidazo[1.2-a]pyridine-3-formaldehyde pure product. According to the preparation method, thereaction raw materials are easy to obtain, the price is reasonable, the reaction conditions are mild, operation is easy, aftertreatment is simple, and the product is stable in quality and high in purity.

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

PHOSPHOTIDYLINOSITOL 3-KINASE INHIBITORS

This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.